Advertisement

Topics

Nivolumab for Subtype of Metastatic Colon Cancer

06:57 EDT 3 Aug 2017 | Medscape

All patients with metastatic colorectal cancer should be screened for the genetic defect dMMR/MSI-H because they may respond to immunotherapy.
Medscape Medical News

Original Article: Nivolumab for Subtype of Metastatic Colon Cancer

NEXT ARTICLE

More From BioPortfolio on "Nivolumab for Subtype of Metastatic Colon Cancer"

Quick Search
Advertisement
 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...